Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger
Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025.
Atrium Therapeutics Inc. (RNA)
Market is closed
News See All
15 Stocks with the Biggest Hedge Fund Momentum
On February 23, Bloomberg News reported that during the week ended February 19, hedge funds registered record-high net sales of global stocks, the highest since early April 2025.
Avidity Biosciences, Inc. (RNA): A Bull Case Theory
We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on RNA.
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger
Earlier in the week, Novartis said it entered into an agreement with Avidity Biosciences, Inc.
Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis
In a statement over the weekend, Novartis said that it entered into an agreement with Avidity Biosciences, Inc.
What Makes Avidity Biosciences (RNA) an Investment Choice?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating
In a market note, BofA Securities gave a “buy” recommendation for Avidity Biosciences Inc.’s (NASDAQ:RNA) stock with a price target of $65, an increase from the $56 previously.
11 Best Stocks to Buy for the Next 3 Months According to Hedge Funds
On September 6, Rebecca Patterson, Chief Investment Strategist at Bridgewater Associates, appeared in an interview on CNBC to discuss the current US economy.
Avidity (RNA) Gets 26% Jump on Potential Takeover
Avidity Biosciences rallied for a third day on Wednesday, jumping 26.14 percent to close at $48.26 as investors gobbled up shares following reports that it received an acquisition bid from Swiss drugmaker...
Hedge Fund Resource Center